Poster Presenter

An Innovative New Natural Anti-diabetic Agent with Intracellular Mechanisms of Action
Slavko Ivkovic and Danko Brezak
Croatia

In this work a new natural substance (ADD7) for Diabetes Mellitus Type I and II treatment is presented. It has been developed using the technology which provides the synergism of activated Clinoptilolite nano- and micro-particles and 6 phytopharmacological active substances. ADD7 has been tested in the three multi-centric control clinical trials showing strong anti-diabetic effect and no side effects or toxic consequences for liver, kidney and other organs which is particularly important in the sense of long term application. It stimulates intracellular cascade pathways, thus increasing glucose transport through the cell membrane, and has direct effect on the PKB/act which is essentially involved in the signal pathways responsible for the metabolic effect of insulin. Furthermore, it is tyrosine kinase activator, which leads to the tyrosine phosphorylation and to the creation of ATP. ADD7 has antioxidative effect by preventing LDL-oxidation and development of atherosclerotic plaque in the blood vessels, preventing development of oxidative stress and increasing the effect of antioxidative cell enzymes - Glutathione dismutase (SOD), Glutathione peroxidase (GPx) and Glutathione reductase (GR), whose activities are reduced in diabetic patients. It protects beta cells of the pancreas from autoimmune and oxidative damages, inhibits the damages after oxidative stress in other cells, and influences on the autoimmune reaction by means of CD56 reduction. In the conducted studies it was also noticed that ADD7 decreases HbA1c and increases C-Peptide. Thereby, it stimulates binding of C-peptide to a receptor and activation of signal transduction pathways that result in a stimulation of Na/K ATPase and endothelial nitric oxide synthase.